Adagio Therapeutics racks up $50m Series A

Waltham, Massachusetts-based Adagio Therapeutics Inc, a developer of antibodies for coronaviruses, has raised $50 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this